Zhongguo aizheng zazhi (May 2023)

The value of surgery in the patients with de novo stage Ⅳ breast cancer

  • CHEN Luyan, WANG Lixue, FU Peifen

DOI
https://doi.org/10.19401/j.cnki.1007-3639.2023.05.002
Journal volume & issue
Vol. 33, no. 5
pp. 431 – 436

Abstract

Read online

Breast cancer is one of the common malignant tumors in the world. About 6% of the patients are de novo stage Ⅳ breast cancer, which is incurable. Traditionally, the role of surgery has been confined to relieving symptoms, improving quality of life and reducing tumor load. Nowadays, a multidisciplinary team is a prerequisite for optimal management, and patients with oligometastatic lesion always live for a long time. R0 resection of the primary and metastatic foci can extend the time of progression-free survival (PFS), which may bring survival benefits. Therefore, whether to perform surgery has become a hot clinical issue. This article deeply discussed extensively the surgical value in de novo stage Ⅳ breast cancer patients.

Keywords